Header Logo

Connection

Andrew Ambrosy to Humans

Back to Details
This is a "connection" page, showing publications Andrew Ambrosy has written about Humans.
Andrew Ambrosy
Connection Strength
3.224
Humans
  1. Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations. J Am Coll Cardiol. 2025 Sep 09; 86(10):725-734.
    View in: PubMed
    Score: 0.070
  2. A spotlight on congestion in acute heart failure: a joint session with the Romanian Society of Cardiology (part I). Heart Fail Rev. 2025 Sep; 30(5):883-898.
    View in: PubMed
    Score: 0.069
  3. Outpatient worsening heart failure: innovative decongestion strategies and health equity implications. Heart Fail Rev. 2025 Sep; 30(5):831-841.
    View in: PubMed
    Score: 0.068
  4. Clinical and research applications of natural language processing for heart failure. Heart Fail Rev. 2025 Mar; 30(2):407-415.
    View in: PubMed
    Score: 0.067
  5. Inpatient Use of Guideline-Directed Medical Therapy During Heart?Failure Hospitalizations Among Community-Based Health Systems. JACC Heart Fail. 2025 Jan; 13(1):43-54.
    View in: PubMed
    Score: 0.066
  6. Medical Decision-Making and Revascularization in Ischemic Cardiomyopathy. Med Clin North Am. 2024 May; 108(3):553-566.
    View in: PubMed
    Score: 0.062
  7. Fluid Restriction Recommendations in Heart Failure: Dry as a Bone or Quench Your Thirst? J Card Fail. 2022 10; 28(10):1531-1533.
    View in: PubMed
    Score: 0.057
  8. Analysis of Worsening Heart Failure Events in an Integrated Health Care System. J Am Coll Cardiol. 2022 Jul 12; 80(2):111-122.
    View in: PubMed
    Score: 0.056
  9. Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVID-19 pandemic. Clin Cardiol. 2022 Feb; 45(2):180-188.
    View in: PubMed
    Score: 0.055
  10. A Natural Language Processing-Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Netw Open. 2021 11 01; 4(11):e2135152.
    View in: PubMed
    Score: 0.054
  11. Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021 10 19; 10(20):e020377.
    View in: PubMed
    Score: 0.054
  12. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021 05; 235:54-64.
    View in: PubMed
    Score: 0.051
  13. Improving adherence to guideline-directed medical therapies and outcomes in the developing world: A call to end global inequities in heart failure. Int J Cardiol. 2021 04 15; 329:74-76.
    View in: PubMed
    Score: 0.051
  14. Hospitalizations for heart failure and mortality risk during the evolving coronavirus disease 2019 pandemic - the wave may break but a dangerous undertow persists. Eur J Heart Fail. 2020 12; 22(12):2225-2227.
    View in: PubMed
    Score: 0.050
  15. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol. 2020 09 01; 76(9):1034-1048.
    View in: PubMed
    Score: 0.050
  16. Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns. Eur J Heart Fail. 2020 10; 22(10):1752-1754.
    View in: PubMed
    Score: 0.049
  17. Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest. Eur J Heart Fail. 2020 09; 22(9):1734-1736.
    View in: PubMed
    Score: 0.049
  18. A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. Int J Cardiol. 2020 06 15; 309:95-99.
    View in: PubMed
    Score: 0.048
  19. Hyperglycemia and outcomes in acute heart failure - A bittersweet relationship. Int J Cardiol. 2020 02 01; 300:196-197.
    View in: PubMed
    Score: 0.047
  20. Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? Eur J Heart Fail. 2019 11; 21(11):1398-1401.
    View in: PubMed
    Score: 0.046
  21. A Balancing Act: Preserving Renal Function and the Need for Decongestion. J Card Fail. 2019 08; 25(8):643-644.
    View in: PubMed
    Score: 0.046
  22. In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail. 2019 08; 21(8):1008-1011.
    View in: PubMed
    Score: 0.046
  23. Applying data science approaches to identify frequent flyers in heart failure: rise of the machines. Eur J Heart Fail. 2019 03; 21(3):319-321.
    View in: PubMed
    Score: 0.045
  24. Combination drug therapy in heart failure: greater than the sum of its parts. Eur J Heart Fail. 2018 09; 20(9):1323-1325.
    View in: PubMed
    Score: 0.043
  25. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. Eur J Heart Fail. 2018 06; 20(6):963-972.
    View in: PubMed
    Score: 0.042
  26. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J. 2018 05; 199:176-177.
    View in: PubMed
    Score: 0.042
  27. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. Am Heart J. 2018 05; 199:97-104.
    View in: PubMed
    Score: 0.042
  28. Sudden cardiac death following admission for acute heart failure: adding insult to injury. Eur J Heart Fail. 2018 03; 20(3):533-535.
    View in: PubMed
    Score: 0.041
  29. Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement. Eur J Heart Fail. 2017 11; 19(11):1424-1426.
    View in: PubMed
    Score: 0.040
  30. Clinical profiles in acute heart failure: one size fits all or not at all? Eur J Heart Fail. 2017 10; 19(10):1255-1257.
    View in: PubMed
    Score: 0.040
  31. Clinical trials in acute heart failure: beginning of the end or end of the beginning? Eur J Heart Fail. 2017 11; 19(11):1358-1360.
    View in: PubMed
    Score: 0.040
  32. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). Am J Cardiol. 2017 07 01; 120(1):98-105.
    View in: PubMed
    Score: 0.039
  33. Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. Am Heart J. 2017 Apr; 186:130-138.
    View in: PubMed
    Score: 0.039
  34. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. JACC Heart Fail. 2017 01; 5(1):1-13.
    View in: PubMed
    Score: 0.039
  35. Targeting digoxin dosing to serum concentration: is the bullseye too small? Eur J Heart Fail. 2016 08; 18(8):1082-4.
    View in: PubMed
    Score: 0.037
  36. Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. JACC Heart Fail. 2016 05; 4(5):365-7.
    View in: PubMed
    Score: 0.037
  37. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
    View in: PubMed
    Score: 0.037
  38. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2016 Mar; 18(3):306-13.
    View in: PubMed
    Score: 0.035
  39. Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. Heart Fail Clin. 2015 Oct; 11(4):581-9.
    View in: PubMed
    Score: 0.035
  40. Effect of minor liver function test abnormalities and values within the normal range on survival in heart failure. Am J Cardiol. 2015 Apr 01; 115(7):938-41.
    View in: PubMed
    Score: 0.034
  41. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep. 2014 Dec; 11(4):416-27.
    View in: PubMed
    Score: 0.033
  42. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13; 63(18):1823-32.
    View in: PubMed
    Score: 0.032
  43. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01; 63(12):1123-1133.
    View in: PubMed
    Score: 0.031
  44. The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013 Jun; 2(2):99-108.
    View in: PubMed
    Score: 0.030
  45. Not time to RELAX in acute heart failure. Lancet. 2013 May 25; 381(9880):1813.
    View in: PubMed
    Score: 0.030
  46. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013 Mar; 34(11):835-43.
    View in: PubMed
    Score: 0.029
  47. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb; 165(2):216-25.
    View in: PubMed
    Score: 0.029
  48. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012 Dec 01; 110(11):1623-6.
    View in: PubMed
    Score: 0.029
  49. B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. J Cardiovasc Med (Hagerstown). 2012 Jun; 13(6):360-7.
    View in: PubMed
    Score: 0.028
  50. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012 Mar; 14(3):302-11.
    View in: PubMed
    Score: 0.028
  51. Acute heart failure syndromes: assessment and reconstructing the heart. J Cardiovasc Med (Hagerstown). 2011 Apr; 12(4):258-63.
    View in: PubMed
    Score: 0.026
  52. Tolvaptan for the treatment of heart failure: a review of the literature. Expert Opin Pharmacother. 2011 Apr; 12(6):961-76.
    View in: PubMed
    Score: 0.026
  53. Heart failure in 2010: one step forward, two steps back. Nat Rev Cardiol. 2011 Feb; 8(2):72-3.
    View in: PubMed
    Score: 0.026
  54. Use of a prescription opioid registry to examine opioid misuse and overdose in an integrated health system. Prev Med. 2018 05; 110:31-37.
    View in: PubMed
    Score: 0.021
  55. The role of marijuana use disorder in predicting emergency department and inpatient encounters: A retrospective cohort study. Drug Alcohol Depend. 2017 09 01; 178:170-175.
    View in: PubMed
    Score: 0.020
  56. Marijuana use and service utilization among adolescents 7 years post substance use treatment. Drug Alcohol Depend. 2016 Nov 01; 168:1-7.
    View in: PubMed
    Score: 0.019
  57. Predictors of Incident Heart?Failure Diagnosis Setting: Insights From the Veterans Affairs Healthcare System. JACC Heart Fail. 2023 03; 11(3):347-358.
    View in: PubMed
    Score: 0.015
  58. Predicting short-term outcomes after transcatheter aortic valve replacement for aortic stenosis. Am Heart J. 2023 02; 256:60-72.
    View in: PubMed
    Score: 0.014
  59. Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):175-181.
    View in: PubMed
    Score: 0.014
  60. Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. ESC Heart Fail. 2022 12; 9(6):3713-3736.
    View in: PubMed
    Score: 0.014
  61. Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020. Am J Cardiol. 2022 11 15; 183:129-136.
    View in: PubMed
    Score: 0.014
  62. Effect of Medically Tailored Meals on Clinical Outcomes in Recently Hospitalized High-Risk Adults. Med Care. 2022 10 01; 60(10):750-758.
    View in: PubMed
    Score: 0.014
  63. Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician. Curr Atheroscler Rep. 2022 Jul; 24(7):563-570.
    View in: PubMed
    Score: 0.014
  64. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022 May; 247:76-89.
    View in: PubMed
    Score: 0.014
  65. Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study. BMJ Open. 2022 01 31; 12(1):e048755.
    View in: PubMed
    Score: 0.014
  66. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. ESC Heart Fail. 2022 04; 9(2):947-952.
    View in: PubMed
    Score: 0.014
  67. Temporal trends in the outcomes of acute heart failure: between consolatory evidences and real progress. Eur J Heart Fail. 2021 03; 23(3):432-435.
    View in: PubMed
    Score: 0.013
  68. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Feb 05; 22(1):115.
    View in: PubMed
    Score: 0.013
  69. Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. Mayo Clin Proc. 2021 02; 96(2):503-506.
    View in: PubMed
    Score: 0.013
  70. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021 01 31; 16(1):9.
    View in: PubMed
    Score: 0.013
  71. Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. ESC Heart Fail. 2021 02; 8(1):662-669.
    View in: PubMed
    Score: 0.013
  72. The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality. Cardiology. 2021; 146(1):49-59.
    View in: PubMed
    Score: 0.013
  73. Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. JACC Cardiovasc Interv. 2020 10 26; 13(20):2331-2341.
    View in: PubMed
    Score: 0.013
  74. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. JACC Heart Fail. 2020 10; 8(10):859-866.
    View in: PubMed
    Score: 0.012
  75. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health. 2010 Dec; 100(12):2541-7.
    View in: PubMed
    Score: 0.012
  76. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
    View in: PubMed
    Score: 0.012
  77. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiol. 2020 06 01; 5(6):643-651.
    View in: PubMed
    Score: 0.012
  78. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med. 2020 08 13; 383(7):691-693.
    View in: PubMed
    Score: 0.012
  79. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. Circ Heart Fail. 2020 05; 13(5):e006758.
    View in: PubMed
    Score: 0.012
  80. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. Eur J Heart Fail. 2020 06; 22(6):1022-1031.
    View in: PubMed
    Score: 0.012
  81. One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. Eur J Heart Fail. 2020 05; 22(5):859-867.
    View in: PubMed
    Score: 0.012
  82. Spontaneous Coronary Artery Dissection and Incident Ventricular Arrhythmias: Frequency, Clinical Characteristics, and Outcomes. JACC Cardiovasc Interv. 2020 02 24; 13(4):539-541.
    View in: PubMed
    Score: 0.012
  83. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
    View in: PubMed
    Score: 0.012
  84. A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). J Cardiovasc Transl Res. 2020 08; 13(4):540-548.
    View in: PubMed
    Score: 0.012
  85. Association between systolic ejection time and outcomes in heart failure by ejection fraction. Eur J Heart Fail. 2020 07; 22(7):1174-1182.
    View in: PubMed
    Score: 0.012
  86. Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017. JAMA Cardiol. 2019 12 01; 4(12):1280-1286.
    View in: PubMed
    Score: 0.012
  87. Statin Therapy and Risk of Incident Diabetes Mellitus in Adults With Cardiovascular Risk Factors. Am J Cardiol. 2020 02 15; 125(4):534-541.
    View in: PubMed
    Score: 0.012
  88. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? Am Heart J. 2020 02; 220:97-107.
    View in: PubMed
    Score: 0.012
  89. Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. Eur J Heart Fail. 2019 11; 21(11):1472-1476.
    View in: PubMed
    Score: 0.012
  90. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. Can J Cardiol. 2019 09; 35(9):1097-1105.
    View in: PubMed
    Score: 0.011
  91. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. Eur J Heart Fail. 2018 12; 20(12):1760-1763.
    View in: PubMed
    Score: 0.011
  92. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 02 07; 380(6):539-548.
    View in: PubMed
    Score: 0.011
  93. Self-initiated tobacco cessation and substance use outcomes among adolescents entering substance use treatment in a managed care organization. Addict Behav. 2009 Feb; 34(2):171-9.
    View in: PubMed
    Score: 0.011
  94. Characteristics of patients with substance use disorder before and after the Affordable Care Act. Drug Alcohol Depend. 2018 12 01; 193:124-130.
    View in: PubMed
    Score: 0.011
  95. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018 12; 5(6):1035-1043.
    View in: PubMed
    Score: 0.011
  96. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev. 2018 07; 23(4):597-607.
    View in: PubMed
    Score: 0.011
  97. Improving Postdischarge Outcomes in Acute Heart Failure. Am J Ther. 2018 Jul/Aug; 25(4):e475-e486.
    View in: PubMed
    Score: 0.011
  98. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
    View in: PubMed
    Score: 0.010
  99. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2018 02; 20(2):304-314.
    View in: PubMed
    Score: 0.010
  100. Lessons learned in acute heart failure. Eur J Heart Fail. 2018 04; 20(4):630-641.
    View in: PubMed
    Score: 0.010
  101. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. Eur J Heart Fail. 2018 02; 20(2):281-291.
    View in: PubMed
    Score: 0.010
  102. Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. Curr Cardiol Rep. 2017 08; 19(8):71.
    View in: PubMed
    Score: 0.010
  103. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27; 69(25):3029-3039.
    View in: PubMed
    Score: 0.010
  104. Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. JACC Heart Fail. 2017 04; 5(4):311-312.
    View in: PubMed
    Score: 0.010
  105. Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. Curr Heart Fail Rep. 2017 02; 14(1):30-39.
    View in: PubMed
    Score: 0.010
  106. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017 04; 19(4):552-562.
    View in: PubMed
    Score: 0.009
  107. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circ Heart Fail. 2016 09; 9(9).
    View in: PubMed
    Score: 0.009
  108. Natriuretic peptide-guided management in heart failure. J Cardiovasc Med (Hagerstown). 2016 Aug; 17(8):556-68.
    View in: PubMed
    Score: 0.009
  109. Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. JACC Heart Fail. 2016 06; 4(6):419-27.
    View in: PubMed
    Score: 0.009
  110. Adolescents entering chemical dependency treatment in private managed care: ethnic differences in treatment initiation and retention. J Adolesc Health. 2006 Apr; 38(4):343-50.
    View in: PubMed
    Score: 0.009
  111. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
    View in: PubMed
    Score: 0.009
  112. Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. J Cardiovasc Med (Hagerstown). 2016 Feb; 17(2):92-104.
    View in: PubMed
    Score: 0.009
  113. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
    View in: PubMed
    Score: 0.009
  114. Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. Heart Fail Clin. 2015 Oct; 11(4):591-601.
    View in: PubMed
    Score: 0.009
  115. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. Eur J Heart Fail. 2015 Oct; 17(10):1022-31.
    View in: PubMed
    Score: 0.009
  116. Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. J Cardiovasc Med (Hagerstown). 2015 May; 16(5):331-40.
    View in: PubMed
    Score: 0.009
  117. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May; 17(5):527-33.
    View in: PubMed
    Score: 0.008
  118. Lipids, statins, and clinical outcomes in heart failure: rethinking the data. Heart Fail Rev. 2014 Nov; 19(6):695-8.
    View in: PubMed
    Score: 0.008
  119. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
    View in: PubMed
    Score: 0.008
  120. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J. 2014 Aug; 168(2):142-9.
    View in: PubMed
    Score: 0.008
  121. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circ Heart Fail. 2014 May; 7(3):401-8.
    View in: PubMed
    Score: 0.008
  122. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol. 2013 Dec 01; 112(11):1763-9.
    View in: PubMed
    Score: 0.008
  123. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
    View in: PubMed
    Score: 0.008
  124. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013 Mar; 18(2):107-22.
    View in: PubMed
    Score: 0.007
  125. Hepatic abscess with biliary communication following transarterial chemoembolization of hepatocellular carcinoma. Dig Dis Sci. 2013 Sep; 58(9):2463-5.
    View in: PubMed
    Score: 0.007
  126. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
    View in: PubMed
    Score: 0.007
  127. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2013 Jan; 6(1):47-52.
    View in: PubMed
    Score: 0.007
  128. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
    View in: PubMed
    Score: 0.007
  129. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2013 Feb 15; 111(4):574-81.
    View in: PubMed
    Score: 0.007
  130. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec; 164(6):884-92.e2.
    View in: PubMed
    Score: 0.007
  131. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2012 Nov; 5(6):750-8.
    View in: PubMed
    Score: 0.007
  132. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.
    View in: PubMed
    Score: 0.007
  133. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012 Jul; 18(7):515-23.
    View in: PubMed
    Score: 0.007
  134. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012 May; 17(3):485-509.
    View in: PubMed
    Score: 0.007
  135. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med. 2011 Aug; 12(63):141-51.
    View in: PubMed
    Score: 0.007
  136. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72.
    View in: PubMed
    Score: 0.007
  137. Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experience. J Cardiovasc Med (Hagerstown). 2011 Jul; 12(7):460-8.
    View in: PubMed
    Score: 0.007
  138. The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. Am Heart J. 2011 Jul; 162(1):142-53.e1.
    View in: PubMed
    Score: 0.007
  139. Recurrent headaches in children: an epidemiological survey of two middle schools in inner city Chicago. Pain Pract. 2010 May-Jun; 10(3):214-21.
    View in: PubMed
    Score: 0.006
  140. Parent-assisted or nurse-assisted epidural analgesia: is this feasible in pediatric patients? Paediatr Anaesth. 2009 Nov; 19(11):1084-9.
    View in: PubMed
    Score: 0.006
  141. Unilateral groin surgery in children: will the addition of an ultrasound-guided ilioinguinal nerve block enhance the duration of analgesia of a single-shot caudal block? Paediatr Anaesth. 2009 Sep; 19(9):892-8.
    View in: PubMed
    Score: 0.006
  142. Organizational determinants of outpatient substance abuse treatment duration in women. J Subst Abuse Treat. 2009 Jul; 37(1):64-72.
    View in: PubMed
    Score: 0.005

© 2025 Kaiser Permanente

Your Privacy Choices